PERITONEAL DIALYSIS - RISK FACTOR FOR GLYCEMIC



associated condition

mellitus

disease.

VARIABILITY



Cristina Văduva*, Simona Popa**, Maria Moța**, Eugen Moța***

which is a

diabetes

vascular

Haemodialysis Center, Emergency Hospital Craiova, IHS Craiova, ** Clinical Centre of Diabetes, Nutrition, Metabolic Diseases, University of Medicine and Pharmacy Craiova, *** Nephrology Department, University of Medicine and Pharmacy Craiova

50th ERA-EDTA Congress, Istanbul, 2013

BACKGROUND

In patients with chronic kidney disease

insulin resistance is a quasi-permanent

fundamental cause of type 2

and

We have studied 23 subjects: 9 non diabetic PD patients (4 M, 5 F) and 14 volunteers healthy subjects (3 M, 11 F). All PD patients were adequately dialyzed with Kt /V> 1.7. Patients had different dialitic treatment regimens, four of them used Icodextrine in nocturnal exchange and four had only glucose 1.36% for all exchanges. CGMS was performed in all subjects over a period of 72 hours using

METHODS

Glucose daily load in peritoneal dialysis

aterosclerotic

(PD) patients is an additional risk factor for metabolic disorders in these patients.

Aims of study is to analyze the influence of peritoneal dialysis on glycemic variability certain indices recorded by CGMS (continuous glucose monitoring system) in non diabetic uraemic patients on peritoneal dialysis vs healthy subjects.

Analyzed parameters:


- ☐ HbA1c
- ☐ mean interstitial glucose (MIG)

the DexCom SEVEN CGMS device.

- ☐ standard deviation (SD)
- □ % CV percentage coefficient of variation calculated as SD / glucose mean ratio
- ☐ CONGA (Continuous overall net glycemic action) 1h, 2h, 4h or 6h assesing glycemic variability in predetermined time window.
- CGMS parameters were analyzed in two consecutive days of recording.

PATIENTS CHARACTERISTICS		
Variables	nonPD	PD
	Mean±SD	Mean±SD
	1st Day	2 nd Day
Age	31,2±5,1	60,2±8,4*
BMI	22,8±2,0	28,6±4,6*
HbA1c	5,3±0,2	5,6±0,3*
DP age	-	4,4±2,0
GDL	-	98,7±17,2
Mean - 1stDay	99,7±11,1	118,3±13,8*
Mean - 2ndDay	100,3±9,5	121,8±17,3*
SD - 1stDay	10,5±3,0	18,1±4,8*
SD - 2ndDay	10,5±4,3	18,0±4,8*
%CV - 1stDay	10,5±2,9	15,3±3,8*
%CV - 2ndDay	10,4±3,6	14,8±3,4*
CONGA1h - 1stDay	10,9±2,2	18,4±3,7*
CONGA1h - 2ndDay	10,3±2,8	18,9±8,0*
CONGA2h - 1stDay	12,9±3,1	23,0±5,8*
CONGA2h - 2ndDay	12,3±3,6	23,3±10,5*
CONGA4h - 1stDay	14,0±5,0	25,6±6,2*
CONGA4h - 2ndDay	14,0±4,5	23,5±9,6*
CONGA6h - 1stDay	14,2±4,9	27,3±7,3*
CONGA6h - 2ndDay	13,7±4,6	24,3±8,5*

RESULTS



CONCLUSION

REFERENCES

Non-diabetic uraemic PD patients had both higher glycemic variability and metabolic disorders more emphasized compared with healthy subjects, these differences can be explained at least in part by daily intake of glucose.

Skubala A, Zywiec J, Zełobowska K, Gumprecht J, Grzeszczak W. Continuousglucose monitoring system in 72-hour glucose profile assessment in patients with end-stage renal disease on maintenance continuous ambulatory peritoneal dialysis.Med Sci Monit. 2010 Feb Jennifer Marshall, Peter Jennings, Adrian Scott, Richard J. Fluck, Christopher W. Mcintyre, Glycemic control in diabetic CAPD patients assessed by continuous bglucose monitoring system (CGMS) Kidney International, Vol.

64 (2003), pp. 1480–1486 Mrinal K. Dasgupta, Strategies for Managing Diabetic Patients on Peritoneal Dialysis, Advances in Peritoneal Dialysis, Vol. 20, 2004





